Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Keros Therapeutics ( (KROS) ) is now available.
On August 28, 2025, Keros Therapeutics announced that its President and CEO, Jasbir Seehra, will participate in two upcoming healthcare conferences. These events include a fireside chat at the Wells Fargo Healthcare Conference on September 4, 2025, and a corporate presentation at the H.C. Wainwright Global Investment Conference on September 9, 2025. The participation in these conferences highlights Keros’ ongoing efforts to engage with the investment community and stakeholders, potentially impacting its industry positioning and visibility.
The most recent analyst rating on (KROS) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
Keros Therapeutics’ overall score reflects strong financial performance and positive corporate events, offset by valuation concerns and technical indicators suggesting potential overbought conditions. The strategic realignment and workforce reduction add uncertainty, impacting the overall score.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company is a leader in understanding the role of these proteins, which regulate the growth, repair, and maintenance of various tissues. Keros’ lead product candidate, KER-065, targets neuromuscular diseases, particularly Duchenne muscular dystrophy, while its most advanced candidate, elritercept, is aimed at treating cytopenias in myelodysplastic syndrome and myelofibrosis.
Average Trading Volume: 526,079
Technical Sentiment Signal: Hold
Current Market Cap: $605.6M
See more data about KROS stock on TipRanks’ Stock Analysis page.